Izotziaja (Isotretinoin)

Isotretinoin acts by binding to retinoic acid receptors in skin cells, which leads to reduced size and activity of sebaceous glands, lower sebum production, normalization of follicular keratinization, and anti‑inflammatory effects. These actions collectively address the key pathogenic factors of acne.

The appropriate amount of Izotziaja to apply is determined by the prescribing healthcare professional based on the severity of acne, skin type, and individual response. Patients should follow the specific instructions provided by their prescriber and not alter the regimen without medical advice.

Isotretinoin is classified as pregnancy category X because it is highly teratogenic. It should not be used by pregnant individuals, and effective contraception is required during treatment and for a defined period after discontinuation. Use during breastfeeding is also not recommended, as the drug can be excreted in milk.

To order Izotziaja, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details and any necessary import documentation.

Compared with oral isotretinoin, topical Izotziaja delivers the active ingredient directly to the skin, resulting in lower systemic exposure and a reduced risk of systemic side effects. Relative to other topical retinoids such as adapalene or tretinoin, isotretinoin may provide stronger sebaceous gland suppression, but it can also be more irritating, so tolerability varies among patients.

Store Izotziaja at room temperature below 25 °C, in its original packaging, protected from moisture and direct light. Keep the container tightly closed when not in use. Do not freeze the product, and keep it out of reach of children.

Izotziaja is applied topically to clean, dry skin. A thin layer is spread over the affected areas, usually once daily or as directed by the prescriber. Hands should be washed before and after application, and patients should avoid contact with eyes, lips and mucous membranes.

Serious risks include severe skin reactions such as exfoliative dermatitis, allergic responses like urticaria or angioedema, and ocular irritation. Although systemic absorption is limited, signs of hypervitaminosis A (e.g., headache, nausea, liver enzyme changes) may occur in rare cases and require immediate medical evaluation.

Izotziaja should not be used by individuals who are pregnant, planning to become pregnant, or breastfeeding. It is also contraindicated in patients with known hypersensitivity to isotretinoin or any component of the formulation, and in those who are concurrently using systemic retinoids or high‑dose vitamin A supplements.